Study of YA-101 for multiple system atrophy
Part of Brain & nervous system clinical trials.
This trial tests if a new oral medication, YA-101, can help people with multiple system atrophy (MSA), a rare brain condition. It aims to see if the drug is safe and works for both types of MSA (parkinsonian and cerebellar).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with multiple system atrophy (MSA) by a doctor using current guidelines.
- You can walk on your own without help from another person.
- You are able to swallow and take oral medications.
- You do not have serious health issues like advanced heart, lung, liver, or kidney disease, uncontrolled diabetes, or a recent stomach ulcer.
- You do not have a history of major brain problems like stroke, epilepsy, or severe head injury.
- You do not have an active viral infection such as HIV, hepatitis B, or hepatitis C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called TEV-56286 for people with Multiple System Atrophy (MSA), a rare brain disorder. It aims to see if the drug can help control symptoms and slow the disease.
This trial tests whether the drug TEV-56286 continues to work for multiple system atrophy (a rare brain disorder). It is for people who already completed a previous study of the same drug.
This early-phase trial tests a new drug called ALT001 for people with multiple system atrophy (MSA). It aims to see if the drug is safe and may help slow the disease.
This study tests a new antibody drug that targets a protein linked to multiple system atrophy (MSA). It aims to see if the drug is safe and may slow the disease, for people recently diagnosed.
This Phase 1 study checks how safe a drug called ION464 is, how the body handles it, and how much of the drug reaches the bloodstream in adults with multiple system atrophy (MSA). It may help researchers find a dosing approach for future treatments for MSA.
This trial tests whether a medication called butylphthalide can help slow or improve symptoms of multiple system atrophy (MSA), a rare neurological condition that affects movement, balance, and automatic body functions. The study will measure how well the drug works and how safe it is for patients.
Hear when a new Multiple System Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.